EIRGENIX, INC. OFFICIALLY OPENS ITS NEW WORLD-CLASS COMMERCIAL MASS PRODUCTION FACILITY
2019/01/23 – Today, EirGenix, Inc. (6589) held its opening ceremony to commemorate the launch of its new ‘Protein Drug Commercial Mass Production Plant’ in Hsinchu (Zhubei) Biomedical Park. This event marks an important step for EirGenix in achieving international standards in order to break into the global market; a milestone that has been planned since the company’s inception in 2012. At the landmark ceremony, over 200 guests were in attendance to express their support and encouragement for the company’s promising future. EirGenix was also joined by esteemed guests from China, Japan, Europe, and the United States, demonstrating the company’s already established reputation within the international community.
EirGenix’s new mass production plant in Zhubei is a state-of-the-art facility, furnished with the latest technology in biologic manufacturing. The plant is equipped with the most advanced 2000-liter single-use bioreactors and has a capacity to accommodate two (3 x 2000-liter bioreactor) production lines. These single-use bioreactors, coupled with traditional technologies, allow downstream development processes to achieve the maximum efficiency and flexibility to meet different product and stage development needs. At present, only the first production line is officially open with two 2 x 2000-liter bioreactors (four 2000-liter reactors total) installed. Once both production lines are in operation, the plant hopes to achieve a monoclonal antibody production capacity of 1000 kg per year. The strategy to phase the expansion of the plant’s production is to allow it to organically grow with the company’s future needs, which will be fueled by rising domestic and foreign demand for EirGenix’s services as a contract development and manufacturing organization (CDMO), and its own proprietary drug products.
EirGenix currently stands amongst a small minority of professional biopharmaceutical companies within Asia to be known for its reputable CDMO services. Since its establishment, EirGenix has been completed over 10 international service contracts that it has been entrusted to handle. In concert with the opening ceremony, EirGenix has just completed a three-way partnership agreement with Spain’s Oncomatryx and Taiwan’s Formosa Laboratories (4746) to commission an antibody drug conjugate (ADC) that has been in development for several years under EirGenix and Formosa Laboratories. All three parties finalized the contract signing at the opening ceremony in high spirits to mark the launch of their new cooperation. The formation of such agreements is just one illustration of the expanse of domestic and foreign business EirGenix has established over the last few years. The company continues to secure more contracts, steadily adding more domestic customers to its client base, while also expanding its client reach overseas to areas such as China, Japan, Europe, and the United States. The previous year was also a momentous year for EirGenix, which included the approval of phase 3 clinical trials for its proprietary EG12014 biosimilar product, as well as the addition of three other biosimilars into its product pipeline that will likely have significant sales potential in the growing biosimilar market. While the establishment of the new plant will undoubtedly provide the necessary capacity for the development of these promising in-house products, it will serve to stimulate the demand for late-stage CDMO services from international biopharmaceutical companies. This will surely trigger rapid growth in the coming years for EirGenix, allowing it to propel further onto the international stage.
Just last month on December 18, 2018, EirGenix had registered its filing for an Initial Public Offering (IPO), and as planned, is presently expected to be a listed public company within the year. Moving forth, EirGenix pledges to remain at the forefront of the biotechnology industry by applying the latest technology to generate innovative research and development. It is the aim of EirGenix to maintain its research and manufacturing operations in Taiwan in hopes of cultivating local talents to further develop the capabilities of the domestic biotechnology industry. With hopes of advancing the nation’s visibility and presence in the global market, EirGenix ultimately strives to provide people around the world with access to the best and most affordable medical drugs available.